Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 5/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.43 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.43 |
| ▸ | HSP90AB1 | P08238 | 12/20 | 0.43 |
| ▸ | HSP90AA1 | P07900 | 11/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5508144 | 1.00 | KDM4E (0.45) | KDM4EALDH1A1HPGDADRA1AHSD17B10 | |
| SCHEMBL4570455 | 0.91 | KDM4E (0.44) | KDM4EALDH1A1HPGDADRA1AHSD17B10 | |
| SCHEMBL4572432 | 0.90 | KDM4E (0.47) | KDM4EALDH1A1HPGDADRA1AHSD17B10 | |
| SCHEMBL5509440 | 0.89 | KDM4E (0.44) | KDM4EALDH1A1HPGDADRA1AHSD17B10 | |
| SCHEMBL5509446 | 0.89 | KDM4E (0.44) | KDM4EALDH1A1HPGDADRA1AHSD17B10 | |
| SCHEMBL5513784 | 0.87 | HSP90AB1 (0.46) | HDAC6HDAC1HDAC4HSP90AB1HSP90AA1 | |
| SCHEMBL5513793 | 0.87 | HSP90AB1 (0.46) | HDAC6HDAC1HDAC4HSP90AB1HSP90AA1 | |
| SCHEMBL6473322 | 0.84 | KDM4E (0.40) | KDM4EALDH1A1HPGDADRA1AHSD17B10 | |
| SCHEMBL6473315 | 0.84 | KDM4E (0.40) | KDM4EALDH1A1HPGDADRA1AHSD17B10 | |
| SCHEMBL6472086 | 0.83 | MGMT (0.42) | KDM4EALDH1A1HPGDADRA1AHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100240681-A1 | VALOMACICLOVIR POLYMORPHS | EPIPHANY BIOSCIENCES, INC. (US) | 2010-09-23 | — | — | US | disclosed |
| US-7189849-B2 | Synthesis of acyclic nucleoside derivatives | MEDIVIR AB (SE) | 2007-03-13 | — | — | US | disclosed |
| US-20050250795-A1 | Synthesis of acyclic nucleoside derivatives | MEDIVIR AB (SE) | 2005-11-10 | — | — | US | disclosed |
| EP-1535923-A1 | Synthesis of acyclic nucleoside derivatives | Medivir Aktiebolag (SE) | 2005-06-01 | — | — | EP | disclosed |
| US-6878844-B2 | Synthesis of acyclic nucleoside derivatives | MEDIVIR AB (SE) | 2005-04-12 | — | — | US | disclosed |
| US-20040248910-A1 | Synthesis of acyclic nucleoside derivatives | MEDIVIR AB (SE) | 2004-12-09 | — | — | US | disclosed |
| US-20040024214-A1 | Synthesis of acyclic nucleoside derivatives | MEDIVIR AB (SE) | 2004-02-05 | — | — | US | disclosed |
| US-6613936-B1 | Herpes and retroviral infections; diester derivatives of H2G bearing specific combinations of an amino acid ester and a fatty acid ester, improved oral bioavailability; 9-(2-(butyryloxymethyl)-4-(L-isoleucyloxy)butyl)guanine | MEDIVIR AB (SE) | 2003-09-02 | — | — | US | disclosed |
| EP-1131323-A1 | SYNTHESIS OF ACYCLIC NUCLEOSIDE DERIVATIVES | Medivir Aktiebolag (SE) | 2001-09-12 | — | — | EP | disclosed |
| US-6184376-B1 | POTENT ANTIVIRALS, ESPECIALLY AGAINST HERPES INFECTIONS, SUCH AS THOSE CAUSED BY VARICELLA ZOSTER VIRUS, HERPES SIMPLEX, EPSTEIN-BARR VIRUS, HERPES TYPE 6 (HHV-6) AND TYPE 8 (HHV-8). SHINGLES IN THE ELDERLY OR CHICKEN POX IN THE YOUNG | MEDIVER AB (SE) | 2001-02-06 | — | — | US | disclosed |
| WO-2000008025-A1 | SYNTHESIS OF ACYCLIC NUCLEOSIDE DERIVATIVES | MEDIVIR AB (SE) | 2000-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240681-A1 | VALOMACICLOVIR POLYMORPHS | TYMP, SI, CYP3A4 | KDM4E 931/4885ALDH1A1 3349/4885HPGD 894/4885 |
| US-20040024214-A1 | Synthesis of acyclic nucleoside derivatives | NSUN2, SLC28A1, NUDT1 | KDM4E 4410/4885ALDH1A1 2176/4885HPGD 1298/4885 |
| US-20040248910-A1 | Synthesis of acyclic nucleoside derivatives | NSUN2, SLC28A1, NUDT1 | KDM4E 4410/4885ALDH1A1 2176/4885HPGD 1298/4885 |
| US-20050250795-A1 | Synthesis of acyclic nucleoside derivatives | ASNS, NUDT1, PNP | KDM4E 4268/4885ALDH1A1 2194/4885HPGD 943/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.